Singapore, July 10 -- The Health Sciences Authority received information related to the study titled 'Phase I/II study of Mezigdomide and Elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM)'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr Chng Wee Joo
Published by HT Digital Content Services with permission from Health Daily Digest....